Traws Pharma has completed the Phase I clinical trials of tivoxavir marboxil, a single-dose drug for treating or preventing H5N1 bird flu.
The randomised, placebo-controlled, double-blind trial evaluated the pharmacodynamics (PD), tolerability, pharmacokinetics (PK), and safety of escalating doses in healthy and influenza-negative adult volunteers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,